Rab3D, a member of the Rab GTPase family, plays a critical role in regulating vesicle trafficking and exocytosis, particularly in specialized secretory cells. It is predominantly expressed in tissues with high secretory activity, such as pancreatic acinar cells, adipocytes, and certain endocrine or exocrine glands. Rab3D is involved in the docking and fusion of secretory vesicles to the plasma membrane, facilitating the controlled release of cargo (e.g., enzymes, hormones, or neurotransmitters). Unlike other Rab3 isoforms (Rab3A, B, C), Rab3D exhibits distinct tissue-specific functions, with studies linking it to processes like zymogen granule exocytosis in pancreatic cells and GLUT4 vesicle translocation in adipocytes. Its dysregulation has been associated with metabolic disorders, secretory deficiencies, and certain cancers.
Rab3D antibodies are essential tools for investigating its expression, localization, and functional interactions. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study Rab3D's role in cellular secretion mechanisms or disease contexts. Some antibodies specifically detect post-translational modifications (e.g., GTP-bound states) to assess activation status. Research utilizing these antibodies has highlighted Rab3D's dual role in both promoting and inhibiting secretion, depending on cellular context, underscoring its complex regulatory network. Commercial antibodies are typically validated across human, mouse, and rat models, supporting cross-species comparative studies.